<DOC>
	<DOCNO>NCT00830531</DOCNO>
	<brief_summary>The main goal study obtain pharmacokinetic safety data bumetanide newborns refractory seizure . The overall hypothesis bumetanide , add conventional antiepileptic ( antiseizure ) medication , safe well tolerated medication , compare conventional antiepileptic drug alone .</brief_summary>
	<brief_title>Pilot Study Bumetanide Newborn Seizures</brief_title>
	<detailed_description>Seizures occur often newborn period ( 2-3.5 per 1000 live birth ) later age . Neonatal seizure lead frequent serious long-term consequence survivor , later epilepsy significant cognitive motor disability . Unfortunately completely effective drug treat neonatal seizure . Anti-epileptic drug ( AEDs ) currently use treat neonatal seizure generally ineffective significant potential side effect . Furthermore , many AEDs never test randomized study . Numerous expert thus emphasize last year urgent need randomize trial potential new treatment neonatal seizure . The investigator conduct pilot study drug bumetanide one potential novel treatment . Bumetanide commercially available drug use safely newborns diuretic many year minimal side effect . Recent basic science research animal show bumetanide effective reduce seizure neonatal animal block specific chloride importer highly express neonate child adult ( 1 ) . Moreover , experimental study show bumetanide particularly effective seizure use combination phenobarbital ( PB ) , standard first drug give treat neonatal seizure ( 2 ) . The investigator conduct randomize , double-blind , control , dose escalation study BTN add-on therapy treat refractory seizure cause HIE , focal multi-focal stroke , intracranial hemorrhage , CNS infection , genetic syndrome , focal diffuse brain malformation , idiopathic presume genetic etiology seizure , metabolic disorder electrolyte disturbance cause renal failure control initial loading dose PB . The trial test feasibility early enrollment newborn HIE , rapid application full montage EEG , continuous review EEG data detect refractory seizure soon occur follow initial load dose PB . When EEG-proven seizure occur least 30 minute follow load dose PB , newborn randomize receive either BTN placebo conjunction load dose PB . Clinical , laboratory continuous EEG monitoring data obtain BTN administration analyze determine pharmacokinetics safety BTN compare data treatment standard therapy group . This study address important challenge trial design set stage trial improve treatment neonatal seizure . Data pilot study use guide design planned Phase III multicenter trial test efficacy BTN control refractory neonatal seizure .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<mesh_term>Bumetanide</mesh_term>
	<criteria>newborn postconceptional age 3344 week condition risk seizure : asphyxia intracranial hemorrhage suspect confirmed stroke CNS infection genetic syndrome focal diffuse brain malformation idiopathic presume genetic etiology seizure metabolic disorder electrolyte disturbance cause renal failure suspect clinical seizure transient metabolic abnormality ( e.g. , transient hypocalcemia ) sole cause seizures receive ECMO ( extracorporeal membrane oxygenation ) therapy alteration bumetanide pharmacokinetics ECMO contraindication bumetanide ( determined treat physician ) receive diuretic furosemide BTN newborn total serum bilirubin &gt; 15 mg/dL enrollment newborn give â‰¥ 40mg/kg phenobarbital loading dos AEDs phenobarbital ( receive levetiracetam still eligible since levetiracetam affect bumetanide pharmacokinetics )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypoxic-ischemic encephalopathy</keyword>
	<keyword>Neonatal stroke</keyword>
	<keyword>Intracranial hemorrhage</keyword>
	<keyword>Perinatal asphyxia</keyword>
	<keyword>Neonatal Seizures</keyword>
</DOC>